Navigation Links
PRO-DEX, INC. Announces Fiscal 2009 Fourth Quarter and Full-year Results
Date:9/17/2009

Total liabilities 5,985,000 8,373,000 --------- --------- Commitments and contingencies Shareholders' equity: Common shares; no par value; 50,000,000 shares authorized; 9,964,366 shares issued and 9,668,671 outstanding June 30, 2009 9,879,066 shares issued and 9,803,366 outstanding June 30, 2008 16,574,000 16,545,000 Accumulated deficit (6,092,000) (3,247,000) --------- --------- Total shareholders' equity 10,482,000 13,298,000 Total liabilities and shareholders' equity $16,467,000 $21,671,000 =========== =========== See notes to consolidated financial statements.

                             PRO-DEX, INC. and SUBSIDIARIES
                         CONSOLIDATED STATEMENTS OF OPERATIONS
                                  Years ended June 30

                                                           2009         2008
                                                           ----         ----

    Net sales                                       $21,122,000  $25,126,000

    Cost of sales                                    14,374,000   16,917,000
                                                     ----------   ----------
    Gross profit                                      6,748,000    8,209,000

    Operating expenses:
      Selling expense                                 1,295,000    1,482,000
      General and administrative expenses             3,157,000    3,265,000
      Irvine facility move related general and
       administrative expenses                                -      274,000
      Impairment of intangible
'/>"/>
SOURCE Pro-Dex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Pro-Dex, Inc. Announces Fiscal 2009 Fourth Quarter Financial Results Conference Call and Webcast
2. Pro-Dex, Inc. Announces Fiscal 2009 Third Quarter Financial Results Conference Call and Webcast
3. Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast
4. Pro-Dex, Inc. Provides Updates on Key Developments
5. American Pacific Announces Executive Change
6. United Way of Greater Los Angeles Announces Matching Fund Launched by Two Local Philanthropists
7. Satellite Healthcare Announces the Recipients of the 2009 Norman S. Coplon Extramural Grants
8. AAF(R) Announces MEGAcel(TM) I Filter with Helior(TM) Media
9. SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test
10. Neogen Corporation Announces 1st Quarter Results Conference Call
11. MDS Announces CEO Transition Plan

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...LOSANGELES,Nov.25/PRNewswire-USNewswire/--TheBlack...odetermineexecutiveleadershipfor2010. ,, Thenew...cialtiesinpublicpolicy,law,finance,governmenthealt...eBoardalsocomesfromawiderangeofpersonalbackgrounds...melivingwithHIVthemselves,andrepresentingmultiplea...
(Date:11/25/2009)...erm survivors of testicular cancer who were treate...e side effects, including neurological side effect...t treated with chemotherapy, according to a new st...f the National Cancer Institute . , Marianne Bry... University Hospital, in Bergen, Norway, and colle...
(Date:11/25/2009)...tress increase blood pressure? This simple questi... years. New Stress-related gene Modulates High Bl...blood pressure? This simple question has been the...w research has for the first time established a li...pressure response to stress in mice as well as hum...
(Date:11/25/2009)... Evaluation and treatment clinics... Woodstock (Vocus) November 25, 2009 -- Centegr...vaccines and H1N1 vaccine shots at four Centegra P...r shipment of vaccine has arrived. The clinics are...and McHenry and will be open as follows: , &nb...
(Date:11/25/2009)...positive note, CDC sees few signs of trouble with ...5 (HealthDay News) -- The ongoing H1N1 swine flu p... pneumonias among younger patients, a U.S. health ...crease in serious pneumococcal infections around t...tional Center for Immunization and Respiratory Dis...
Breaking Medicine News(10 mins):Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4
...mericans diagnosed with primary open angle glaucom...or the condition according to a study. Th...rapy use in the U.S. to utilize longitudinal data ...ed 65 and older by analyzing data collected from 1...
...nistration (FDA) today issued a formal written req...l devices remaining in the marketplace, including...ns. On April 17, 2007, U.S. Marshals, at F...'s manufacturing processes. During the seizure, Sh...
...ght not only face the risk of developing health di...they are also likely to face the risk of developi...r 17 years, the study - by researchers at the Canc...for men and 85 for women significantly increases c...
...nistration (FDA) is warning pharmaceutical manufac...essionals who compound medications to be especial... commonly used worldwide in liquid over-the-counte...the agency is issuing guidance to industry recomme...
... as the most brisk walkers in the world, as the sp...en percent in the last decade. In a sampl... on top followed by citizens of Copenhagen, Madrid...the study. But walking fast is not good f...
...Bobby Robson is ready to fight against cancer for ...ho said that he was diagnosed with cancer for the ...y last week after cancerous nodules were discovere...e greatest news I've ever had but I have fought ha...
Other Medicine News:Health News:FDA Advises Manufacturers to Test Glycerin for Possible Contamination 2Health News:Bobby Robson Diagnosed With Cancer for Fifth Time 2
(Date:11/25/2009)...stCall/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevi...sruptivesurgicaltreatmentsforthespine,announcedtod...,2009,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwil...Company,sproductsandwillincludecommentsfrommanagem...l-innumbersare1-877-407-4018fordomesticcallersand1...
(Date:11/25/2009)...portlinker.comannouncesthatanewmarketresearchrepor...elivery-USMarketTrends&Analysis http://www.re...-US-Market-Trends--Analysis.html ,, TheUSintra...erapeuticapplicationsfromthedeliveryofconventional...euticdrugs.Thefutureofthetechnologyhingesontotheef...
(Date:11/25/2009)...ewswire/-- ChemoCentryx,Inc.,announcedtodaythatPh...ProspectiveRandomizedOralTherapyEvaluationinCrohn,...swithmoderate-to-severeCrohn,sdiseasedemonstratedc...profile.Thestudydemonstratedevidenceofclinicaleffi...pointdecreaseintheCrohn,sDiseaseActivityIndex(CDAI...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Study finds colorectal cancer rates increasing worldwide 8769 1Study finds colorectal cancer rates increasing worldwide 8769 2Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 1Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 2Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 3Lumbar Spinal Stenosis Surgery at the Olympia Medical Center 48340 1Lumbar Spinal Stenosis Surgery at the Olympia Medical Center 48340 2
... for Presentation at 47th ICAAC on ..., Sept. 4 Ardea Biosciences,Inc. (Pink Sheets: AR...eted,Phase 1 single-ascending-dose, multiple-ascen...es of RDEA806, a novel HIV non-nucleoside reverse,...eers. The data from these Phase 1 clinical trials...
...ive analysis of,clinical trials known as a meta-an...tent was associated with significantly lower risks...mpared to the Taxus Stent out to 30,months after a...randomized,clinical trials and 8,695 patients, the...ed on the Journal of the American College of Cardi...
Other Medicine Technology:Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 2Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 2Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 4
Anterior Stromal Puncture Cannula, 25 g
Viscoelastic Cannula, 23 g. Angled
Anterior Chamber Needle, 21 g
Anterior Chamber Needle, 25 g. Angled
Medicine Products: